Business of health
DTC Marketing

A focus on diseases for which it believes it can develop more valuable drugs

Feb/04/2010 04:03
images
GlaxoSmithKline said it will stop research into new antidepressants and focus on diseases for which it believes it can develop more valuable drugs, a major shift for a company that developed some of the biggest-selling antidepressants of the past 20 years. The key question is "valuable to who" , investors or patients ? Maybe the reason is because physicians and patients are buying the marketing that led to a lot of people taking antidepressant medications ?

Read More...

Tags:

|

Focus on customers not shareholders

Jan/25/2010 04:59
04_03_3---Stock-Market-Prices_web
"The harder a CEO is pushed to increase shareholder value, the more the CEO will be tempted to make moves that actually hurt the shareholder"* I don't think that anyone can argue that most of the recent moves of the drug industry, acquisitions and mergers, have been more about shareholders than customers.
Read More...

Tags:

|

More Stuff